Semaglutide 2.4 mg and Physical Functioning: Patient-Reported Outcomes from STEP 1-4
Semaglutide 2.4 mg weekly was superior to placebo for physical functioning across the four 68-week STEP 1-4 trials. PICO summary and expert commentary.
GLP-1 Receptor Agonists
Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
Semaglutide and Long-Term Weight Loss in Obesity Without Diabetes: A Prespecified SELECT Analysis
A prespecified analysis of the SELECT trial reports semaglutide produced a mean weight reduction of 10.2 percent versus 1.5 percent for placebo, sustained over four years in adults with cardiovascular disease and obesity but without diabetes. PICO summary and expert commentary.
SELECT Kidney Outcomes
A pre-specified secondary analysis of the SELECT trial found that once-weekly semaglutide 2.4 mg modestly reduced a composite kidney endpoint versus placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes. PICO summary and expert commentary.
STEP-HFpEF
Prespecified pooled analysis of the STEP-HFpEF program shows once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
Semaglutide and Kidney Outcomes in Type 2 Diabetes (FLOW)
In the FLOW randomised controlled trial, weekly semaglutide reduced major kidney disease events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
AI Scoring in Semaglutide NASH Trial
A post hoc analysis testing whether machine-learning digital pathology reproduces pathologist scoring of liver biopsies in a phase II semaglutide NASH trial. PICO summary and expert commentary.
Oral Semaglutide Pharmacokinetics in Healthy Chinese Adults: A Phase 1 Trial
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
Semaglutide and NYHA Functional Class in Obesity-Related HFpEF (STEP-HFpEF Program)
A prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showing that once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
Semaglutide Plus Empagliflozin for NAFLD in T2D: Trial Protocol
A published study protocol for a 52-week double-blind randomised trial of semaglutide plus empagliflozin versus each drug alone for NAFLD in type 2 diabetes. No efficacy results are reported yet. PICO summary and expert commentary.
Cotadutide in Diabetic Kidney Disease (Phase 2b)
A phase 2b trial of the GLP-1/glucagon receptor agonist cotadutide showed dose-dependent reductions in albuminuria in type 2 diabetes with CKD. PICO summary and expert commentary.